CD163 and neoplasm: According to the ratio of anti-inflammatory (CD163+) to pro-inflammatory TAMs, a significant skew towards the pro-inflammatory phenotype was observed in the nsECT2-treated group and tendentiously decreased in nsECT3 and nsECT4-treated mice, compared to untreated tumour-bearing mice (Figure 5F).